MycoBiomDB – Record Details (MyCo_3242)

Biomarker Record Details

Database ID: MyCo_3242
DB IDMyCo_3242
TitleSerum (1-->3) beta-D-glucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS
Year2009
PMID19725788
Fungal Diseases involvedPneumocystis pneumonia
Associated Medical ConditionAIDS
GenusPneumocystis
Speciesjirovecii
OrganismPneumocystis jirovecii
Ethical StatementThis study was approved by the Ethics Review Committee of the hospital (IMCJ-H20-569), International Medical Center of Japan, Tokyo, Japan.
Site of InfectionNone
Opportunistic invasiveNone
Sample typeBody fluid
Sample sourceSerum
Host GroupHuman
Host Common nameHuman
Host Scientific nameHomo sapiens
Biomarker NameBDG
Biomarker Full Name1-3-beta-D-Glucan
Biomarker TypeNegative
BiomoleculeProtein
Geographical LocationJapan
CohortHere evaluated data from 111 consecutive HIV-1– infected patients with PCP at the International Medical Center of Japan, an 885-bed tertiary care hospital in Tokyo, from April 1997 through July 2007.
Cohort No.111
Age GroupNone
P ValueNone
SensitivityNone
SpecificityNone
Positive Predictive ValueNone
MICNone
Fold ChangeNone
PathwayNone
Disease Introduction MechanismPneumocystis pneumonia (PCP) is associated with significant morbidity and mortality in patients with human immnuode- ficiency virus type 1 (HIV-1) infection [1, 2]. PCP is usually diagnosed microscopically by identifying Pneumocystis jirovecii in bronchoalveolar lavage fluid (BALF) or bronchoscopically obtained lung tissue [3]. Bronchoscopy, however, is inva sive, especially in patients with hypoxemia associated with PCP. Therefore, a minimally invasive method is desirable for diagnosis.
TechniqueELISA
Analysis MethodFDA Approved-Fungitell assay
ELISA kitsNone
Assay DataFDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA
Validation Techniques usedFDA Approved-Fungitell assay
Up Regulation Down RegulationNegative
Sequence DataNone
External LinkNone